Flow Cytometry in Drug Discovery and Development

Preface.
Foreword.
Acknowledgements.
Contributors.
Part I Introduction (Philip Marder and VirginiaLitwin).
1 Introduction to Flow Cytometry (Elizabeth Raveche, FatimaAbbasi, Yao Yuan, Erica Salerno, Siddha Kasar and GeraldMarti).
2 Recent Advances in Flow Cytometry: Platforms, Tools and theChallenges for Data Analysis (Paul J Smith, Roy Edward, Rachel JErrington).
3 Introduction to Biomarkers (Ole Vesterqvist and ManjulaReddy).
Part II Flow Cytometry in the Drug Development Process(Virginia Litwin and Philip Marder).
4 HTS Flow Cytometry, Small Molecule Discovery, and the NIHMolecular Libraries Initiative (Larry A. Sklar and Bruce S.Edwards).
5 A Multiparameter Approach to Cell Cycle Analysis as a StandardTool in Oncology Drug Discovery (Carmen Raventos-Suarez andByron H. Long)
6 Flow Cytometry in Pre-Clinical Toxicology/Safety AssessmentEnvironment (David McFarland and Kristi Harkins)
7 Use of Flow Cytometry for Defining and Validating theMolecular Mechanism of Anti-cancer Drugs in Humans (David WHedley).
8 CD4 T cell Assessments in Evaluation of HIV Therapeutics(Thomas N. Denny, Raul Louzao, John Wong and BrookeWalker).
9 A Translational Medicine Approach to Monitoring the ImmuneSystem during Clinical Trials (Virginia Litwin and JamesAndahazy).
10 Immunogenicity Testing Using Flow Cytometry (Denise M.O'Hara and Valerie Theobald).
11 Pharmacokinetics by Flow Cytometry: Recommendations forDevelopment and Validation of Flow Cytometric Method forPharmacokinetic Studies (Yuanxin Xu and Susan MRichards).
Part III Validation and Regulatory Compliance (VirginiaLitwin and Philip Marder).
12 Regulatory Compliance and Method Validation (CarlaHill, Dianna Wu, John Ferbas, Virginia Litwin, ManjulaReddy).
13 Instrument Validation for Regulated Studies (John Ferbasand Michelle Schroeder).
Part IV Future Directions (Virginia Litwin and PhilipMarder).
14 Probability State Modeling: A New Paradigm for CytometricAnalysis (Bruce Bagwell).
15 Phospho Flow Cytometry: Single Cell Signaling Networks inNext Generation Drug Discovery and Patient Stratification (PeterO. Krutzik, Sean C. Bendall, Matthew B. Hale, Jonathan M. Irish,Garry P. Nolan).
Index.